IMMUNSTIMULATION DURCH INTERLEUKIN 2 NACH AUTOLOGER STAMMZELLTRANSPLANTATION BEI KINDERN UND JUGENDLICHEN MIT SOLIDEN TUMOREN

Translated title of the contribution: IL2 therapy post autologous stem cell transplantation stimulates the production of tumor cytotoxic cytokines in children and adolescents with solic tumors

H. J. Laws, D. Dilloo, H. Hanenberg, D. Schwamborn, S. Burdach, U. Gobel

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Children with solid tumors of poor prognosis have benefitted from autologous bone marrow transplantation as a treatment modality. Adjuvant interleukin-2 (IL2) therapy has previously been shown to improve prognosis in adults with some solid tumors. In this setting improved survival probability has been attributed to IL2-mediated augmentation of antineoplastic activity of the immune system. In this study 8 pediatric patients in complete remission after autologous stem cell transplantation were treated with recombinant IL2 administered in 3 cycles of 5 days continuous intravenous infusions and a two week rest inbetween. We demonstrated that IL2 therapy increased transplantation related activation of the immune system both on cellular and humoral levels. Peripheral blood T and NK cell number increased by the factors 1.7 and 6.0 respectively. NK and T cell activation were further enhanced as indicated by elevated levels of soluble IL2 receptor. The production of tumor cytotoxic cytokines like αTNF and γINF was stimulated. The elevated aTNF and γINF cytokine synthesis seemed to be mainly related to the activation and proliferation of NK cells, as T cells obtained from patients after IL2 therapy showed a definite cytokine production deficiency after T cell specific stimulation.

Original languageGerman
Pages (from-to)257-263
Number of pages7
JournalKlinische Padiatrie
Volume205
Issue number4
StatePublished - 1993
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Interleukin-2
Cytokines
Natural Killer Cells
T-Lymphocytes
Neoplasms
Immune System
Therapeutics
Autologous Transplantation
Interleukin-2 Receptors
Bone Marrow Transplantation
Intravenous Infusions
Antineoplastic Agents
Blood Cells
Cell Count
Transplantation
Pediatrics
Survival

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Laws, H. J., Dilloo, D., Hanenberg, H., Schwamborn, D., Burdach, S., & Gobel, U. (1993). IMMUNSTIMULATION DURCH INTERLEUKIN 2 NACH AUTOLOGER STAMMZELLTRANSPLANTATION BEI KINDERN UND JUGENDLICHEN MIT SOLIDEN TUMOREN. Klinische Padiatrie, 205(4), 257-263.

IMMUNSTIMULATION DURCH INTERLEUKIN 2 NACH AUTOLOGER STAMMZELLTRANSPLANTATION BEI KINDERN UND JUGENDLICHEN MIT SOLIDEN TUMOREN. / Laws, H. J.; Dilloo, D.; Hanenberg, H.; Schwamborn, D.; Burdach, S.; Gobel, U.

In: Klinische Padiatrie, Vol. 205, No. 4, 1993, p. 257-263.

Research output: Contribution to journalArticle

Laws, HJ, Dilloo, D, Hanenberg, H, Schwamborn, D, Burdach, S & Gobel, U 1993, 'IMMUNSTIMULATION DURCH INTERLEUKIN 2 NACH AUTOLOGER STAMMZELLTRANSPLANTATION BEI KINDERN UND JUGENDLICHEN MIT SOLIDEN TUMOREN', Klinische Padiatrie, vol. 205, no. 4, pp. 257-263.
Laws, H. J. ; Dilloo, D. ; Hanenberg, H. ; Schwamborn, D. ; Burdach, S. ; Gobel, U. / IMMUNSTIMULATION DURCH INTERLEUKIN 2 NACH AUTOLOGER STAMMZELLTRANSPLANTATION BEI KINDERN UND JUGENDLICHEN MIT SOLIDEN TUMOREN. In: Klinische Padiatrie. 1993 ; Vol. 205, No. 4. pp. 257-263.
@article{004971442a8d490b8d006e9677b5253e,
title = "IMMUNSTIMULATION DURCH INTERLEUKIN 2 NACH AUTOLOGER STAMMZELLTRANSPLANTATION BEI KINDERN UND JUGENDLICHEN MIT SOLIDEN TUMOREN",
abstract = "Children with solid tumors of poor prognosis have benefitted from autologous bone marrow transplantation as a treatment modality. Adjuvant interleukin-2 (IL2) therapy has previously been shown to improve prognosis in adults with some solid tumors. In this setting improved survival probability has been attributed to IL2-mediated augmentation of antineoplastic activity of the immune system. In this study 8 pediatric patients in complete remission after autologous stem cell transplantation were treated with recombinant IL2 administered in 3 cycles of 5 days continuous intravenous infusions and a two week rest inbetween. We demonstrated that IL2 therapy increased transplantation related activation of the immune system both on cellular and humoral levels. Peripheral blood T and NK cell number increased by the factors 1.7 and 6.0 respectively. NK and T cell activation were further enhanced as indicated by elevated levels of soluble IL2 receptor. The production of tumor cytotoxic cytokines like αTNF and γINF was stimulated. The elevated aTNF and γINF cytokine synthesis seemed to be mainly related to the activation and proliferation of NK cells, as T cells obtained from patients after IL2 therapy showed a definite cytokine production deficiency after T cell specific stimulation.",
author = "Laws, {H. J.} and D. Dilloo and H. Hanenberg and D. Schwamborn and S. Burdach and U. Gobel",
year = "1993",
language = "German",
volume = "205",
pages = "257--263",
journal = "Klinische Padiatrie",
issn = "0300-8630",
publisher = "Georg Thieme Verlag",
number = "4",

}

TY - JOUR

T1 - IMMUNSTIMULATION DURCH INTERLEUKIN 2 NACH AUTOLOGER STAMMZELLTRANSPLANTATION BEI KINDERN UND JUGENDLICHEN MIT SOLIDEN TUMOREN

AU - Laws, H. J.

AU - Dilloo, D.

AU - Hanenberg, H.

AU - Schwamborn, D.

AU - Burdach, S.

AU - Gobel, U.

PY - 1993

Y1 - 1993

N2 - Children with solid tumors of poor prognosis have benefitted from autologous bone marrow transplantation as a treatment modality. Adjuvant interleukin-2 (IL2) therapy has previously been shown to improve prognosis in adults with some solid tumors. In this setting improved survival probability has been attributed to IL2-mediated augmentation of antineoplastic activity of the immune system. In this study 8 pediatric patients in complete remission after autologous stem cell transplantation were treated with recombinant IL2 administered in 3 cycles of 5 days continuous intravenous infusions and a two week rest inbetween. We demonstrated that IL2 therapy increased transplantation related activation of the immune system both on cellular and humoral levels. Peripheral blood T and NK cell number increased by the factors 1.7 and 6.0 respectively. NK and T cell activation were further enhanced as indicated by elevated levels of soluble IL2 receptor. The production of tumor cytotoxic cytokines like αTNF and γINF was stimulated. The elevated aTNF and γINF cytokine synthesis seemed to be mainly related to the activation and proliferation of NK cells, as T cells obtained from patients after IL2 therapy showed a definite cytokine production deficiency after T cell specific stimulation.

AB - Children with solid tumors of poor prognosis have benefitted from autologous bone marrow transplantation as a treatment modality. Adjuvant interleukin-2 (IL2) therapy has previously been shown to improve prognosis in adults with some solid tumors. In this setting improved survival probability has been attributed to IL2-mediated augmentation of antineoplastic activity of the immune system. In this study 8 pediatric patients in complete remission after autologous stem cell transplantation were treated with recombinant IL2 administered in 3 cycles of 5 days continuous intravenous infusions and a two week rest inbetween. We demonstrated that IL2 therapy increased transplantation related activation of the immune system both on cellular and humoral levels. Peripheral blood T and NK cell number increased by the factors 1.7 and 6.0 respectively. NK and T cell activation were further enhanced as indicated by elevated levels of soluble IL2 receptor. The production of tumor cytotoxic cytokines like αTNF and γINF was stimulated. The elevated aTNF and γINF cytokine synthesis seemed to be mainly related to the activation and proliferation of NK cells, as T cells obtained from patients after IL2 therapy showed a definite cytokine production deficiency after T cell specific stimulation.

UR - http://www.scopus.com/inward/record.url?scp=0027254503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027254503&partnerID=8YFLogxK

M3 - Article

VL - 205

SP - 257

EP - 263

JO - Klinische Padiatrie

JF - Klinische Padiatrie

SN - 0300-8630

IS - 4

ER -